
Mariana Kaplan
Chief, Systemic Autoimmunity Branch, NIAMS · University of Pennsylvania Health System
Credentials: · ·
History
- Present
Systemic Autoimmunity Branch Division · University of Pennsylvania Health System
PresentNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Systemic Autoimmunity Branch Division · University of Michigan
Present
Rheumatology
National Institute of Medical Sciences and Nutrition
Research
Nature Medicine · 2016 · Last of 10 authors · Corresponding · 1,308 citations
Science Translational Medicine · 2013 · Last of 15 authors · Corresponding · 1,126 citations
The Journal of Immunology · 2011 · Last of 17 authors · 1,028 citations
- SH
39 papers
- SG
28 papers

17 papers · 5 as a fellow

17 papers

16 papers · 7 as a resident
- MJ
14 papers · 2 as a resident

14 papers · 1 as a resident
- PG
14 papers
Grants
- 2009–2013
NETs in the Development of Lupus and Its Cardiovascular Complications
National Heart, Lung, and Blood Institute · R01
Contact PI · $1.5M · University of Michigan at Ann Arbor
- 2007–2013
PPAR-y Agonists, RA and Cardiovascular Disease
National Heart, Lung, and Blood Institute · R01
Contact PI · $1.9M · University of Michigan at Ann Arbor
- 2004–2008
The Role of Dendritic Cell-T Cell Interactions in the p*
National Institute of Arthritis and Musculoskeletal and Skin Diseases · R03
Contact PI · $227.7K · University of Michigan at Ann Arbor
- 2002–2007
Mechanisms of T-Cell Induced-APC Cytotoxicity in Lupus
National Institute of Arthritis and Musculoskeletal and Skin Diseases · K08
Contact PI · $642.6K · University of Michigan at Ann Arbor
Clinical trials
- 2023–2027
Principal investigator · Recruiting · Phase 2
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- 2021–2024
Natural History of Coronavirus Disease (COVID-19) in Systemic Autoimmune Diseases
Principal investigator · Completed
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- 2015–2020
Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)
Principal investigator · Completed · Phase 1, Phase 2
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- 2007–2013
PPAR-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease
Principal investigator · Completed · Phase 3
University of Michigan


